Commentaries on ‘Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections’ with a response from the review authors

Authors

  • Andreas H. Groll,

    1. Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children‘s Hospital Münster, Germany
    Search for more papers by this author
  • Thomas Lehrnbecher,

    Corresponding author
    1. Pediatric Hematology and Oncology, Children’s Hospital III, Johann Wolfgang Goethe University, Frankfurt, Germany
    • Pediatric Hematology and Oncology, Children's Hospital III, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
    Search for more papers by this author
  • Mehreen Arshad,

    Corresponding author
    1. Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, NC, USA
    • Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, NC, USA.
    Search for more papers by this author
  • Daniel K. Benjamin Jr,

    1. Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Search for more papers by this author
  • Michael Cohen-Wolkowiez

    1. Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Search for more papers by this author

Abstract

These are commentaries on a Cochrane review, published in this issue of EBCH, first published as: Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.: CD006343. DOI: 10.1002/14651858.CD006343.pub2.

Further information for this Cochrane review is available in this issue of EBCH in the accompanying Summary article. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. The Cochrane Collaboration

Ancillary